Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 4696 AL 4710

Assessing and treating conversations with partners in Parkinson's disease: A scoping review of the evidence

Thilakaratne R, Loftus AM, Cocks N.

Int J Speech Lang Pathol. 2022 Aug;24(4):427-436. doi: 10.1080/17549507.2021.1978545. Epub 2021 Sep 26.

Unilateral agenesis of internal carotid artery with interparaclinoid and contralateral carotid-anterior cerebral artery anastomoses diagnosed by magnetic resonance angiography: a case report

Yamashita K, Yasaka M, Uchino A, Noguchi T.

Surg Radiol Anat. 2022 Feb;44(2):289-292. doi: 10.1007/s00276-021-02844-0. Epub 2021 Sep 27.

Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions

Gadhavi J, Patel M, Bhatia D, Gupta S.

Biochimie. 2022 Jan;192:38-50. doi: 10.1016/j.biochi.2021.09.012. Epub 2021 Sep 25.

Bio-chemical markers of chronic, non-infectious disease in the human tear film

Alotaibi S, Markoulli M, Ozkan J, Papas E.

Clin Exp Optom. 2022 Mar;105(2):166-176. doi: 10.1080/08164622.2021.1974282. Epub 2021 Sep 30.

Adjusting to living with Parkinson's disease; a meta-ethnography of qualitative research

Wieringa G, Dale M, Eccles FJR.

Disabil Rehabil. 2022 Nov;44(23):6949-6968. doi: 10.1080/09638288.2021.1981467. Epub 2021 Sep 30.

Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease

Kurihara K, Mishima T, Fujioka S, Tsuboi Y.

Expert Opin Drug Saf. 2022 Feb;21(2):137-147. doi: 10.1080/14740338.2022.1988926. Epub 2021 Oct 15.

Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis

Jucaite A, Cselényi Z, Kreisl WC, Rabiner EA, Varrone A, Carson RE, Rinne JO, Savage A, Schou M, Johnström P, Svenningsson P, Rascol O, Meissner WG, Barone P, Seppi K, Kaufmann H, Wenning GK, Poewe W, Farde L.

Mov Disord. 2022 Jan;37(1):119-129. doi: 10.1002/mds.28814. Epub 2021 Oct 5.

Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review

Christou EE, Asproudis I, Asproudis C, Giannakis A, Stefaniotou M, Konitsiotis S.

Semin Ophthalmol. 2022 Apr 3;37(3):399-407. doi: 10.1080/08820538.2021.1987482. Epub 2021 Oct 6.

Ergothioneine: A Stress Vitamin with Antiaging, Vascular, and Neuroprotective Roles?

Paul BD.

Antioxid Redox Signal. 2022 Jun;36(16-18):1306-1317. doi: 10.1089/ars.2021.0043. Epub 2021 Dec 7.

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin

Senkevich K, Rudakou U, Gan-Or Z.

Neuropharmacology. 2022 Jan 1;202:108822. doi: 10.1016/j.neuropharm.2021.108822. Epub 2021 Oct 7.

Rodent models based on endolysosomal genes involved in Parkinson's disease

Sanchiz-Calvo M, Bentea E, Baekelandt V.

Curr Opin Neurobiol. 2022 Feb;72:55-62. doi: 10.1016/j.conb.2021.09.004. Epub 2021 Oct 7.

Functional neurological disorder and somatic symptom disorder in Parkinson's disease

Onofrj M, Russo M, Carrarini C, Delli Pizzi S, Thomas A, Bonanni L, Espay AJ, Sensi SL.

J Neurol Sci. 2022 Feb 15;433:120017. doi: 10.1016/j.jns.2021.120017. Epub 2021 Oct 2.

Parkinsonism in viral, paraneoplastic, and autoimmune diseases

Xing F, Marsili L, Truong DD.

J Neurol Sci. 2022 Feb 15;433:120014. doi: 10.1016/j.jns.2021.120014. Epub 2021 Oct 1.

Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC

Spencer PS.

J Neurol Sci. 2022 Feb 15;433:120021. doi: 10.1016/j.jns.2021.120021. Epub 2021 Oct 2.

Dopaminergic Axons: Key Recitalists in Parkinson's Disease

Mishra AK, Dixit A.

Neurochem Res. 2022 Feb;47(2):234-248. doi: 10.1007/s11064-021-03464-1. Epub 2021 Oct 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias